Selbyville, Delaware, Dec. 17, 2024 (GLOBE NEWSWIRE) --
Attention deficit hyperactivity disorder (ADHD) market size reached a valuation of USD 15.8 billion in 2023 and is anticipated to expand at a CAGR of over 5.1% from 2024 to 2032. This growth is primarily driven by increasing ADHD diagnoses, advancements in diagnostic tools, and the continuous development of innovative treatments. Rising awareness and understanding of ADHD are also contributing factors, leading to greater demand for enhanced diagnosis and treatment options.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/12095
ADHD, a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity, affects both children and adults. The ADHD market covers diagnosis, treatment, and management strategies, offering pharmaceutical therapies, behavioral interventions, diagnostic tools, and support services to improve patient outcomes across age groups. Treatment options are diverse, encompassing both pharmacological and non-pharmacological approaches, with stimulant and non-stimulant medications among the primary solutions.
In the attention deficit hyperactivity disorder market, stimulants account for the majority of sales, valued at USD 11.2 billion in 2023. These medications work by increasing norepinephrine and dopamine levels in the brain, helping improve attention, focus, and impulse control. While stimulants have become a foundational part of ADHD treatment due to their rapid effectiveness, individualized treatment plans and long-term monitoring are essential to manage potential side effects and ensure sustained benefits. Non-stimulant options, though generally less effective, provide alternatives for patients seeking different approaches.
The attention deficit hyperactivity disorder market is segmented by age group, with children representing a substantial share of 67.1% in 2023. Early diagnosis and tailored interventions are vital for children with ADHD, helping them address challenges that impact their academic and social development. Interventions may include behavioral therapy, educational support, and medication as needed.
Gender-wise, males lead the attention deficit hyperactivity disorder market, with a significant portion of diagnoses due to the more visible nature of hyperactive and impulsive behaviors. This higher prevalence has spurred targeted treatment approaches to address the unique challenges males often face in educational and social environments.
Among dosage forms, tablets hold the largest attention deficit hyperactivity disorder market share, reaching USD 9.2 billion in 2023. Tablets, including immediate-release and extended-release formulations, allow flexible dosing for both children and adults. Retail pharmacies play a critical role in distributing ADHD medications, contributing USD 9.3 billion to the market, with benefits including convenience, regular prescription refills, and insurance management support.
In the U.S., the ADHD market is expected to grow at a 5.1% CAGR, reaching USD 10.2 billion by 2032. This growth is driven by high awareness, insurance coverage for treatments, and innovations in digital therapeutic options, enhancing market opportunities.
Request for Report Customization @ https://www.gminsights.com/roc/12095
Major players in attention deficit hyperactivity disorder market include Aytu BioPharma, Eli Lilly and Company, Ironshore, Janssen Pharmaceuticals, Lupin, Mallinckrodt, Novartis, Pfizer, Sun Pharmaceutical, Supernus Pharmaceutical, Takeda Pharmaceutical Company, and Teva Pharmaceutical among others.
Partial Table of Contents (ToC) of the report:
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing ADHD diagnosis rates
3.2.1.2 Advancements in pharmaceutical treatments
3.2.1.3 Increased awareness and education
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of ADHD medications
3.2.2.2 Side effects and concerns with medications
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis
Browse more disease specific drugs industry reports @ https://www.gminsights.com/industry-reports/disease-specific-drugs/82
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
